1. Home
  2. PRG vs MIRM Comparison

PRG vs MIRM Comparison

Compare PRG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$29.98

Market Cap

1.4B

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$78.49

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
MIRM
Founded
2020
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
3.4B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PRG
MIRM
Price
$29.98
$78.49
Analyst Decision
Buy
Strong Buy
Analyst Count
7
11
Target Price
$37.50
$92.45
AVG Volume (30 Days)
665.7K
790.7K
Earning Date
10-22-2025
11-04-2025
Dividend Yield
1.74%
N/A
EPS Growth
10.59
N/A
EPS
3.96
N/A
Revenue
$2,507,179,000.00
$471,794,000.00
Revenue This Year
$1.32
$53.78
Revenue Next Year
$0.64
$19.91
P/E Ratio
$7.56
N/A
Revenue Growth
3.71
53.66
52 Week Low
$23.50
$36.88
52 Week High
$44.43
$79.95

Technical Indicators

Market Signals
Indicator
PRG
MIRM
Relative Strength Index (RSI) 51.51 69.86
Support Level $29.38 $63.23
Resistance Level $31.26 $66.77
Average True Range (ATR) 1.01 3.33
MACD 0.10 0.90
Stochastic Oscillator 60.30 98.15

Price Performance

Historical Comparison
PRG
MIRM

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: